Determining Time to First Treatment for Patients With Chronic Lymphocytic Leukemia (CLL)

The time to progression for CLL can vary greatly between patients with some patients never needing treatment and others with aggressive disease requiring early treatment. For newly diagnosed patients, the uncertainty of the current “wait-and-see approach” can create significant emotional distress.

This study introduces a multivariable model to calculate 2 and 4-year probability of treatment and estimates median time to first treatment. The following markers are independently associated with shorter time to first treatment: three involved lymph node sites, increased size of cervical lymph nodes, presence of 17p deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation status.

I like this approach because it identifies at risk patients and can be used to stratify patients that could benefit from early interventional trials.

Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia.

Speak Your Mind